1Prystowsky E N,Benson D W Jr,Fuster V,et aI.Management of patients with atrial librillation:a statement for healthcare profes- sionals from the subcommittee on electrocardiography and elec- trophysiology, American Heart Association [J ]. Circulation, 1996, 93:1262-1277.
4William B K,Robert D A, Daniel D S,et aI.Epidemiologic features of chronic atrial fibrillation:the Framingham study [J].N Engl J Med, 1982,306:1018-1022.
5Philip A W,Robert D A,William B K.Atrial fibrillation:a major contributor to stroke in the elderly:the Framingham study[J]. Arch Intern Med,1987,147:1561-1564.
6Stroke Prevention in Atrial Fibrillation Investigators.Warfarin versus aspirin for prevention of thromboembolism II study[J]. Lancet, 1994,343:687-691.
7Feinberg W M,Cornell E S,Nightingale S D,et aI.Relationship be- tween prothrombin activation fragments F1,2 and international normalized ratio in patients with atrial fibrillation.Stroke prevention in atrial fibrillation investigators[J].Stroke,1997,28:1101.
10Aguilar M,Hart R.Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous his- tory of stroke or transient ischemic attacks[J]. The Gochrane Database of Systematic Reviews,2005,4:1925.
9Arboix A,Lluis GE,Massons JB,et al.Atrial fibrillation and stroke:clinical presentation of cardioembolic versus atherothrombotic infarction.Int J Cardiol,2000,73:33-42.
10Petersen P,Boysen G,Godtfredsen J,et al.Placebo controlled,randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation.Lancet,1989,338:175-179.
